This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

University Of Washington's Neuro-Oncology Program To Investigate Cell Therapeutics' Drug Candidate OPAXIO™ (Paclitaxel Poliglumex) Plus Radiotherapy For Glioblastoma Multiforme, A Highly Malignant Brain Cancer

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert

About Brown University Oncology Research Group (BrUOG)

The Brown University Oncology Research Group (BrUOG) was created in 1994 to coordinate clinical cancer research for Brown's affiliated hospitals and Warren Alpert Medical School faculty. Since that time more than 3,000 Rhode Islanders have been treated on BrUOG trials at area hospitals. BrUOG's main mission is to improve cancer care through the implementation of innovative, multidisciplinary cancer clinical trials. Before BrUOG was founded, there was no unifying body for such research through which Brown's myriad scientists and physicians could share their ideas on the treatment of cancer. The trials sponsored by BrUOG investigate novel, cutting-edge applications of chemotherapeutic agents, biologic agents, and other cancer treatments.

Today besides the 5 Rhode Island main member hospitals, Rhode Island Hospital, The Miriam Hospital, Women and Infants Hospital, Roger Williams Hospital and Memorial Hospital, BrUOG studies are also implemented in 8 other states nationwide.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective and/or less toxic and effective for the treatment of newly diagnosed high-grade malignant brain tumors such as GBM, including when combined with TMZ and RT, the potential failure of OPAXIO when combined with TMZ and RT to provide PFS and OS responses to newly-diagnosed high-grade malignant brain tumors such as GBM, that the results of the new OPAXIO study may not be positive or be used to plan a phase III study of OPAXIO for approval for use in treating newly diagnosed GBM, that CTI cannot predict or guarantee the pace of patient enrollment in the phase II clinical study comparing OPAXIO to TMZ, UW's and CTI's ability to continue to raise capital as needed to fund this study and its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates such as OPAXIO, and the risk factors listed or described from time to time in CTI's filings with the U.S. Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Clinical Trial Enrollment Contact:

Sandra K. Johnston, PhD, RNT: 206.616.7117E: stonesk@uw.edu

Media Contact:

Dan EramianT: 206.272.4343C: 206.854.1200E: deramian@ctiseattle.com www.CellTherapeutics.com/press_room

Investors Contact:

Ed BellT: 206.282.7100

Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: invest@ctiseattle.com www.CellTherapeutics.com/investors

Medical Information Contact:

T: 800.715.0944E: info@askarm.com

SOURCE Cell Therapeutics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,062.53 -59.48 -0.35%
S&P 500 1,994.95 -5.17 -0.26%
NASDAQ 4,558.6130 -11.0080 -0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs